

Title (en)
BENZENESULFONAMIDE-COMPOUND TREATMENT OF A PATHOLOGICAL CONDITION LINKED TO AN EXCESSIVE EFFECT OF TNF

Title (de)
BEHANDLUNG EINES KRANKHEITZUSTANDES IN VERBINDUNG MIT ÜBERMÄSSIGER TNF-WIRKUNG MIT EINER
BENZOLSULFONAMIDVERBINDUNG

Title (fr)
TRAITEMENT D'UNE PATHOLOGIE LIEE A UN EFFET EXCESSIF DU TNF PAR UN COMPOSE DE BENZENE SULFONAMIDE

Publication
EP 2595620 A2 20130529 (FR)

Application
EP 11754705 A 20110719

Priority
• US 201161443132 P 20110215
• FR 1055867 A 20100719
• FR 2011051742 W 20110719

Abstract (en)
[origin: WO2012017166A2] or an addition salt thereof with pharmaceutically acceptable acids, for use thereof in a method for treatment of a pathological condition linked to an excessive effect of TNF-alpha and for use thereof in a method for treatment of the human or animal body as a direct TNF-alpha inhibitor.

IPC 8 full level
A61K 31/18 (2006.01); **A61K 31/343** (2006.01); **A61K 31/352** (2006.01); **A61K 31/403** (2006.01); **A61K 31/495** (2006.01);
A61K 31/502 (2006.01); **A61P 19/02** (2006.01); **A61P 29/00** (2006.01); **C07D 207/48** (2006.01); **C07D 211/62** (2006.01); **C07D 217/06** (2006.01);
C07D 231/08 (2006.01); **C07D 295/215** (2006.01); **C07D 295/26** (2006.01); **C07D 307/06** (2006.01); **C07D 307/84** (2006.01);
C07D 307/92 (2006.01); **C07D 311/34** (2006.01); **C07D 317/50** (2006.01); **C07D 319/18** (2006.01); **C07D 401/08** (2006.01)

CPC (source: EP US)
A61K 31/18 (2013.01 - EP US); **A61K 31/343** (2013.01 - EP US); **A61K 31/352** (2013.01 - EP US); **A61K 31/403** (2013.01 - EP US);
A61K 31/495 (2013.01 - EP US); **A61K 31/502** (2013.01 - EP US); **A61K 45/06** (2013.01 - US); **A61P 1/00** (2017.12 - EP);
A61P 3/10 (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **C07C 311/21** (2013.01 - EP US);
C07C 311/29 (2013.01 - EP US); **C07D 207/38** (2013.01 - EP US); **C07D 207/48** (2013.01 - EP US); **C07D 237/34** (2013.01 - EP US);
C07D 241/04 (2013.01 - EP US); **C07D 295/185** (2013.01 - EP US); **C07D 295/215** (2013.01 - EP US); **C07D 295/26** (2013.01 - EP US);
C07D 307/79 (2013.01 - EP US); **C07D 307/91** (2013.01 - EP US); **C07D 307/92** (2013.01 - EP US); **C07D 309/38** (2013.01 - EP US);
C07D 317/66 (2013.01 - EP US); **C07D 319/18** (2013.01 - EP US); **C07D 405/12** (2013.01 - EP US); **A61K 2121/00** (2013.01 - US);
C07C 2603/20 (2017.04 - EP US); **Y02A 50/30** (2017.12 - EP US)

Citation (search report)
See references of WO 2012017166A2

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
FR 2962649 A1 20120120; CA 2805206 A1 20120209; EP 2595620 A2 20130529; US 2013123266 A1 20130516; US 8975399 B2 20150310;
WO 2012017166 A2 20120209; WO 2012017166 A3 20120719

DOCDB simple family (application)
FR 1055867 A 20100719; CA 2805206 A 20110719; EP 11754705 A 20110719; FR 2011051742 W 20110719; US 201113811144 A 20110719